Literature DB >> 33320831

MANAGEMENT OF ENDOCRINE DISEASE: Gonadal dysfunction in congenital adrenal hyperplasia.

Hedi L Claahsen-van der Grinten1, Nike Stikkelbroeck2, Henrik Falhammar3,4, Nicole Reisch5.   

Abstract

Gonadal dysfunction is an adverse outcome in patients with congenital adrenal hyperplasia (CAH), which may become apparent already during puberty. Clinical consequences of gonadal dysfunction include menstrual disturbances in females and hypogonadism and impaired fertility in males and females. In males, gonadal dysfunction can be caused by primary gonadal failure due to testicular adrenal rest tumours (TART), and by secondary gonadal failure due to poor hormonal control. In females, gonadal dysfunction can result from an overproduction of adrenal androgens including 11-oxygenated C-19 androgens and progestins, and rarely from ovarian adrenal rest tumours. In all patients with CAH, optimal hormonal control is the key for adequate gonadal function. Therefore, regular measurements of adrenal steroids and/or their metabolites should be performed. In addition, markers of the hypothalamus-pituitary-gonadal axis need to be assessed. In females, the regularity of the menstrual cycle should be evaluated. In males, regular evaluation for TART using ultrasonography is recommended from the start of puberty or even earlier when poor hormonal control is present. When TART is present, counselling on cryopreservation of semen should be offered.

Entities:  

Year:  2021        PMID: 33320831     DOI: 10.1530/EJE-20-1093

Source DB:  PubMed          Journal:  Eur J Endocrinol        ISSN: 0804-4643            Impact factor:   6.664


  10 in total

Review 1.  Adrenal myelolipomas.

Authors:  Jan Calissendorff; Carl Christofer Juhlin; Anders Sundin; Irina Bancos; Henrik Falhammar
Journal:  Lancet Diabetes Endocrinol       Date:  2021-08-24       Impact factor: 32.069

Review 2.  Congenital Adrenal Hyperplasia-Current Insights in Pathophysiology, Diagnostics, and Management.

Authors:  Hedi L Claahsen-van der Grinten; Phyllis W Speiser; S Faisal Ahmed; Wiebke Arlt; Richard J Auchus; Henrik Falhammar; Christa E Flück; Leonardo Guasti; Angela Huebner; Barbara B M Kortmann; Nils Krone; Deborah P Merke; Walter L Miller; Anna Nordenström; Nicole Reisch; David E Sandberg; Nike M M L Stikkelbroeck; Philippe Touraine; Agustini Utari; Stefan A Wudy; Perrin C White
Journal:  Endocr Rev       Date:  2022-01-12       Impact factor: 19.871

Review 3.  Management challenges and therapeutic advances in congenital adrenal hyperplasia.

Authors:  Ashwini Mallappa; Deborah P Merke
Journal:  Nat Rev Endocrinol       Date:  2022-04-11       Impact factor: 47.564

Review 4.  Disorders of Sex Development of Adrenal Origin.

Authors:  Gabriela P Finkielstain; Ana Vieites; Ignacio Bergadá; Rodolfo A Rey
Journal:  Front Endocrinol (Lausanne)       Date:  2021-12-20       Impact factor: 5.555

5.  Production of 11-Oxygenated Androgens by Testicular Adrenal Rest Tumors.

Authors:  Mariska A M Schröder; Adina F Turcu; Patrick O'Day; Antonius E van Herwaarden; Paul N Span; Richard J Auchus; Fred C G J Sweep; Hedi L Claahsen-van der Grinten
Journal:  J Clin Endocrinol Metab       Date:  2022-01-01       Impact factor: 5.958

Review 6.  Characteristics of In2G Variant in Congenital Adrenal Hyperplasia Due to 21-Hydroxylase Deficiency.

Authors:  Mirjana Kocova; Paola Concolino; Henrik Falhammar
Journal:  Front Endocrinol (Lausanne)       Date:  2022-01-24       Impact factor: 5.555

Review 7.  Long-Term Outcomes of Congenital Adrenal Hyperplasia.

Authors:  Anna Nordenström; Svetlana Lajic; Henrik Falhammar
Journal:  Endocrinol Metab (Seoul)       Date:  2022-07-08

8.  Emphasizing Pulmonary Function With Respiratory Therapy in an Infant With Congenital Adrenal Hyperplasia, Bronchopneumonia and Leptomeningitis.

Authors:  Pratik R Jaiswal; Pallavi Bhakaney; Vaishnavi Yadav; Moli Jain; Vishnu Vardhan
Journal:  Cureus       Date:  2022-09-01

9.  Increased Prevalence of Fractures in Congenital Adrenal Hyperplasia: A Swedish Population-based National Cohort Study.

Authors:  Henrik Falhammar; Louise Frisén; Angelica Lindén Hirschberg; Agneta Nordenskjöld; Catarina Almqvist; Anna Nordenström
Journal:  J Clin Endocrinol Metab       Date:  2022-01-18       Impact factor: 5.958

10.  The Neuroactive Steroid Pregnanolone Glutamate: Anticonvulsant Effect, Metabolites and Its Effect on Neurosteroid Levels in Developing Rat Brains.

Authors:  Eva Kudova; Pavel Mares; Martin Hill; Katerina Vondrakova; Grygoriy Tsenov; Hana Chodounska; Hana Kubova; Karel Vales
Journal:  Pharmaceuticals (Basel)       Date:  2021-12-30
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.